Business Description
Xencor Inc
NAICS : 325412
SIC : 2834
ISIN : US98401F1057
Compare
Compare
Traded in other countries / regions
XNCR.USAXE9.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2013-12-03Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.15 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -1.25 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 1.35 | |||||
| Beneish M-Score | 0.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28 | |||||
| 3-Year FCF Growth Rate | -81.7 | |||||
| 3-Year Book Growth Rate | -7.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 8.07 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 25.51 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.99 | |||||
| 9-Day RSI | 27.56 | |||||
| 14-Day RSI | 26.81 | |||||
| 3-1 Month Momentum % | -33.76 | |||||
| 6-1 Month Momentum % | 4.01 | |||||
| 12-1 Month Momentum % | -26.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.61 | |||||
| Quick Ratio | 6.61 | |||||
| Cash Ratio | 5.69 | |||||
| Days Sales Outstanding | 83.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | -20.09 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -161.47 | |||||
| Net Margin % | -210.53 | |||||
| FCF Margin % | -191.6 | |||||
| ROE % | -35.9 | |||||
| ROA % | -25.22 | |||||
| ROIC % | -46.31 | |||||
| 3-Year ROIIC % | 498.01 | |||||
| ROC (Joel Greenblatt) % | -180.1 | |||||
| ROCE % | -23.61 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.6 | |||||
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.52 | |||||
| EV-to-EBIT | -3.8 | |||||
| EV-to-EBITDA | -4.04 | |||||
| EV-to-Revenue | 6.81 | |||||
| EV-to-Forward-Revenue | 4.02 | |||||
| EV-to-FCF | -3.85 | |||||
| Price-to-GF-Value | 1.08 | |||||
| Price-to-Projected-FCF | 129.18 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 3.29 | |||||
| Price-to-Net-Cash | 4.47 | |||||
| Earnings Yield (Greenblatt) % | -26.32 | |||||
| FCF Yield % | -21.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XNCR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xencor Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 110.493 | ||
| EPS (TTM) ($) | -3.63 | ||
| Beta | 0.74 | ||
| 3-Year Sharpe Ratio | -0.35 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 50.53 | ||
| 14-Day RSI | 26.81 | ||
| 14-Day ATR ($) | 0.889184 | ||
| 20-Day SMA ($) | 16.0825 | ||
| 12-1 Month Momentum % | -26.03 | ||
| 52-Week Range ($) | 13.83 - 27.24 | ||
| Shares Outstanding (Mil) | 70.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xencor Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xencor Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xencor Inc Frequently Asked Questions
What is Xencor Inc(XNCR)'s stock price today?
The current price of XNCR is $14.22. The 52 week high of XNCR is $27.24 and 52 week low is $13.83.
When is next earnings date of Xencor Inc(XNCR)?
The next earnings date of Xencor Inc(XNCR) is 2025-05-09 Est..
Does Xencor Inc(XNCR) pay dividends? If so, how much?
Xencor Inc(XNCR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers